Nexgel (NXGLW) Cash from Investing Activities (2020 - 2025)
Nexgel's (NXGLW) quarterly Cash from Investing Activities came in at -$40000.0 in Q4 2025, up 36.51% YoY from -$29302.3 in Q4 2024, and down 400.0% on a QoQ basis from -$8000.0 in Q3 2025.
Nexgel (NXGLW) Cash from Investing Activities (2020 - 2025) Analysis & Trends
Nexgel (NXGLW) has 6 years of Cash from Investing Activities data on file, last reported at -$40000.0 in Q4 2025.
- Quarterly Cash from Investing Activities rose 36.51% year-over-year to -$40000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$119000.0 (up 84.65% YoY) and the FY2025 annual result came in at -$68000.0, up 91.23% from the prior year.
- Cash from Investing Activities retreated to -$40000.0 in Q4 2025, from -$8000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $4.1 million in Q2 2023 to a low of -$5.4 million in Q2 2022.
- A 5-year average of -$139437.5 and a median of -$51500.0 in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities tumbled 26600.0% — and 2022, when it surged 290.91%.
- Tracing NXGLW's Cash from Investing Activities over 5 years: stood at $121000.0 in 2021, then surged by 290.91% to $473000.0 in 2022, then tumbled by 157.72% to -$273000.0 in 2023, then soared by 76.92% to -$63000.0 in 2024, then jumped by 36.51% to -$40000.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$40000.0 (Q4 2025), -$8000.0 (Q3 2025), and -$63000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | -26.60 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | -241.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | -222.00 Mn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | -383.65 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | -461.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | -43.20 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | -87.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | -90.00 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | -117.00 Mn |
| 10 | Nexgel | 194,000.44 | -994,999.56 | 1.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -40,000.00 |
| Dec 31, 2025 | -40,000.00 |
| Sep 30, 2025 | -8,000.00 |
| Sep 30, 2025 | -8,000.00 |
| Dec 31, 2024 | -63,000.00 |
| Dec 31, 2024 | -63,000.00 |
| Sep 30, 2024 | -8,000.00 |
| Sep 30, 2024 | -8,000.00 |
| Jun 30, 2024 | -586,000.00 |
| Jun 30, 2024 | -586,000.00 |
| Mar 31, 2024 | -118,000.00 |
| Mar 31, 2024 | -118,000.00 |
| Dec 31, 2023 | -273,000.00 |
| Dec 31, 2023 | -273,000.00 |
| Sep 30, 2023 | 210,000.00 |
| Sep 30, 2023 | 210,000.00 |
| Jun 30, 2023 | 4.12 Mn |
| Jun 30, 2023 | 4.12 Mn |
| Mar 31, 2023 | 397,000.00 |
| Mar 31, 2023 | 397,000.00 |